Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer
- PMID: 29202403
- DOI: 10.1016/j.ejmech.2017.11.065
Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer
Abstract
Eukaryotic elongation factor 2 kinase (eEF2K) is a Ca2+/calmudulin-dependent protein kinase, belonging to a small family of an atypical Ser/Thr-protein kinase. eEF2K has been recently reported to be highly activated or overexpressed in many types of cancer; therefore, eEF2K would be regarded as a promising therapeutic target. In this study, we discovered a β-phenylalanine scaffold by virtual high-throughput screening, as well as designed and synthesized 46 derivatives with assessment of inhibition activity against eEF2K and cytotoxicity. After several rounds of kinase and anti-proliferative activity screening, we discovered an eEF2K inhibitor (21l) with best eEF2K enzymatic activity (IC50 of 5.5 μM) and anti-proliferative activity (MDA-MB-231 cells, IC50 of 12.6 μM, MDA-MB-436 cells, IC50 of 19.8 μM). Moreover, we found that 21l could induce cell death via the apoptotic pathways in MDA-MB-231 and MDA-MB-436 cells. Subsequently, we evaluated its anti-tumor activity and apoptosis-inducing mechanisms in vivo. These results suggested that 21l inhibited tumor growth by apoptosis in the xenograft mouse model of breast cancer (MDA-MB-231 and MDA-MB-436). Collectively, our results demonstrate a novel small-molecule inhibitor targeting eEF2K with mechanism of apoptosis and a therapeutic potential in breast cancer.
Keywords: Anti-tumor activity; Apoptosis; Breast cancer; Eukaryotic elongation factor 2 kinase; β-phenylalanine scaffold.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.Eur J Med Chem. 2018 Jan 20;144:517-528. doi: 10.1016/j.ejmech.2017.12.046. Epub 2017 Dec 14. Eur J Med Chem. 2018. PMID: 29288948
-
Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells.Mol Biosyst. 2016 Mar;12(3):729-36. doi: 10.1039/c5mb00848d. Epub 2016 Jan 18. Mol Biosyst. 2016. PMID: 26776155
-
Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.J Med Chem. 2021 Jul 8;64(13):8870-8883. doi: 10.1021/acs.jmedchem.0c02218. Epub 2021 Jun 23. J Med Chem. 2021. PMID: 34162208 Review.
-
Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells.Eur J Med Chem. 2020 Oct 15;204:112505. doi: 10.1016/j.ejmech.2020.112505. Epub 2020 Jul 18. Eur J Med Chem. 2020. PMID: 32717479
-
Targeting eukaryotic elongation factor 2 kinase (eEF2K) with small-molecule inhibitors for cancer therapy.Drug Discov Today. 2024 Oct;29(10):104155. doi: 10.1016/j.drudis.2024.104155. Epub 2024 Aug 28. Drug Discov Today. 2024. PMID: 39214495 Review.
Cited by
-
Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation.Molecules. 2022 Jul 30;27(15):4886. doi: 10.3390/molecules27154886. Molecules. 2022. PMID: 35956836 Free PMC article.
-
Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.J Mol Med (Berl). 2020 Jun;98(6):775-787. doi: 10.1007/s00109-020-01917-8. Epub 2020 May 7. J Mol Med (Berl). 2020. PMID: 32377852 Review.
-
In-Silico Screening-Based Discovery of New Natural eEF2K Inhibitors with Neuritogenic Activity.ACS Med Chem Lett. 2025 Mar 4;16(3):475-482. doi: 10.1021/acsmedchemlett.4c00635. eCollection 2025 Mar 13. ACS Med Chem Lett. 2025. PMID: 40104800
-
Genetic susceptibility association between viral infection and colorectal cancer risk: a two-sample Mendelian randomization analysis.Infect Agent Cancer. 2024 Aug 10;19(1):37. doi: 10.1186/s13027-024-00602-6. Infect Agent Cancer. 2024. PMID: 39123209 Free PMC article.
-
Insights Into the Pathologic Roles and Regulation of Eukaryotic Elongation Factor-2 Kinase.Front Mol Biosci. 2021 Aug 31;8:727863. doi: 10.3389/fmolb.2021.727863. eCollection 2021. Front Mol Biosci. 2021. PMID: 34532346 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical
Miscellaneous